iosBio
2 known investors
Find your way into iosBio
395 people in our graph share verified history with the iosBio team — schools, employers, funds. One of them is your warm intro.
Alix Tricotunlockedknows Elliot Bland · together at Queen Mary University of London (overlapped)
knows the team · via Imperial College London
×4knows the team · via Queen Mary University of London
×4knows the team · via AstraZeneca
×2knows the team · via University of Westminster
iosBio develops oral, thermostable vaccine candidates using its ESD platform, with a lead program (OraPro-EBV) targeting Epstein-Barr Virus. The company operates in the biotechnology and vaccine development sector.
Founders & leadership
WC
Wayne ChannoninExecutive ChairmanWayne Channon holds a degree in mathematical physics from Imperial College and worked as a systems engineer at IBM. He founded Persona, a networking and communications distributor that grew to €500m in revenue and listed on the London Stock Exchange, and has since founded multiple technology and life sciences companies including Cells4Life and CyteTech. He chairs iosBio, which develops oral thermostable vaccine candidates.
EB
Elliot BlandinCOOElliot Bland is COO at iosBio and a life science executive with a PhD in immunology and expertise in vaccine development, including patent work on EBV antigens. He has previously held senior operations and business development roles at early-stage biotechnology companies, with experience in fundraising, licensing, and regulatory navigation.
CL
Craig LaferrièreinCDO
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- IOSBIO LTD
- Company number
- 04497290
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 29 Jul 2002
- Registered office
- Hayworthe House, Market Place, Haywards Heath, RH16 1DB
- Nature of business (SIC)
- 86900 — Other human health activities
- Previous names
- STABILITECH BIOPHARMA LTD (2016–2020)STABILITECH LTD (2002–2016)
- Accounts
- last made up to 31 Jul 2025 · next due 30 Apr 2027
- Confirmation statement
- last made up to 5 Nov 2025 · next due 19 Nov 2026
Current officers · 6
- Colin Neil Maltby — secretary, appointed 26 Aug 2020
- Elliot Bland — director, appointed 16 Jan 2018
- Wayne Matthew Channon — director, appointed 26 Mar 2007
- Peter John Cozens — director, appointed 5 Feb 2009
- Craig Antony Joseph Laferriere — director, appointed 16 Jul 2024
- Myra Nicole Waiman — director, appointed 6 Jan 2015
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does iosBio do?
- iosBio develops oral, thermostable vaccine candidates using its ESD platform, with a lead program (OraPro-EBV) targeting Epstein-Barr Virus. The company operates in the biotechnology and vaccine development sector.
- Who are iosBio's investors?
- iosBio's investors include Innvotec Ltd., Shackleton Ventures Ltd..